Articles with public access mandates - Jaime Rodriguez-CanalesLearn more
Not available anywhere: 7
Development and validation of a predictive radiomics model for clinical outcomes in stage I non-small cell lung cancer
W Yu, C Tang, BP Hobbs, X Li, EJ Koay, II Wistuba, B Sepesi, C Behrens, ...
International Journal of Radiation Oncology* Biology* Physics 102 (4), 1090-1097, 2018
Mandates: US National Institutes of Health, National Natural Science Foundation of China
TBCRC-010: phase I/II study of dasatinib in combination with zoledronic acid for the treatment of breast cancer bone metastasis
Z Mitri, R Nanda, K Blackwell, CM Costelloe, I Hood, C Wei, AM Brewster, ...
Clinical Cancer Research 22 (23), 5706-5712, 2016
Mandates: Susan G. Komen
Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers
A Weissferdt, J Rodriguez-Canales, H Liu, J Fujimoto, II Wistuba, ...
Human Pathology 46 (3), 376-383, 2015
Mandates: US National Institutes of Health
Programmed death cell ligand 1 (pd-l1) is associated with survival in stage I non–small cell lung cancer
B Sepesi, EP Cuentas, JR Canales, C Behrens, AM Correa, A Vaporciyan, ...
Seminars in thoracic and cardiovascular surgery 29 (3), 408-415, 2017
Mandates: US Department of Defense, US National Institutes of Health
Female gender predicts augmented immune infiltration in lung adenocarcinoma
C Behrens, P Rocha, ER Parra, L Feng, J Rodriguez-Canales, LM Solis, ...
Clinical Lung Cancer 22 (3), e415-e424, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Imaging-genetic data mapping for clinical outcome prediction via supervised conditional gaussian graphical model
X Zhu, J Yao, G Xiao, Y Xie, J Rodriguez-Canales, ER Parra, C Behrens, ...
2016 IEEE international conference on bioinformatics and biomedicine (BIBM …, 2016
Mandates: US National Science Foundation
Optimal molecular profiling of tissue and tissue components: defining the best processing and microdissection methods for biomedical applications
J Rodriguez-Canales, JC Hanson, JD Hipp, UJ Balis, MA Tangrea, ...
Pancreatic Cancer: Methods and Protocols, 61-120, 2013
Mandates: US National Institutes of Health
Available somewhere: 120
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
Mandates: US National Institutes of Health, V Foundation, USA
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
HA Tawbi, M Burgess, V Bolejack, BA Van Tine, SM Schuetze, J Hu, ...
The Lancet Oncology 18 (11), 1493-1501, 2017
Mandates: US National Institutes of Health
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
Mandates: US National Institutes of Health, V Foundation, USA
Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5
XP Yang, K Ghoreschi, SM Steward-Tharp, J Rodriguez-Canales, J Zhu, ...
Nature immunology 12 (3), 247-254, 2011
Mandates: US National Institutes of Health
Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma
FF Lang, C Conrad, C Gomez-Manzano, WKA Yung, R Sawaya, ...
Journal of clinical oncology 36 (14), 1419-1427, 2018
Mandates: US National Institutes of Health
A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition
MP Mak, P Tong, L Diao, RJ Cardnell, DL Gibbons, WN William, ...
Clinical Cancer Research 22 (3), 609-620, 2016
Mandates: US National Institutes of Health, LUNGevity Foundation, USA, V Foundation, USA
CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li, PA Villalobos, ...
Cancer discovery 8 (9), 1156-1175, 2018
Mandates: US National Institutes of Health, National Natural Science Foundation of China
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
J Kim, Z Hu, L Cai, K Li, E Choi, B Faubert, D Bezwada, ...
Nature 546 (7656), 168-172, 2017
Mandates: US National Institutes of Health, Howard Hughes Medical Institute
Fatty acid oxidation mediated by Acyl-CoA synthetase long chain 3 is required for mutant KRAS lung tumorigenesis
MS Padanad, G Konstantinidou, N Venkateswaran, M Melegari, S Rindhe, ...
Cell reports 16 (6), 1614-1628, 2016
Mandates: US National Institutes of Health
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ...
Scientific reports 7 (1), 13380, 2017
Mandates: US National Institutes of Health
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors
I Petrini, PS Meltzer, IK Kim, M Lucchi, KS Park, G Fontanini, J Gao, ...
Nature genetics 46 (8), 844-849, 2014
Mandates: US National Institutes of Health
The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
JM Taube, G Akturk, M Angelo, EL Engle, S Gnjatic, S Greenbaum, ...
Journal for immunotherapy of cancer 8 (1), 2020
Mandates: US National Institutes of Health
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
J Kim, E McMillan, HS Kim, N Venkateswaran, G Makkar, ...
Nature 538 (7623), 114-117, 2016
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program